« Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway », NJPS, vol. 40, nᵒ 2, p. 251–262, déc. 2025, doi: 10.54548/.